Artiva Biotherapeutics, Inc. - 10-Q Filing

Artiva Biotherapeutics reports Q3 2025 financial results including research and development expenses and updates on GC Cell license agreements.

3 articles from 1 source · updated November 9, 2026, 21:13 UTC

Coverage

• Editas Medicine, Inc. - 10-Q Filing SEC EDGAR · November 9, 2026, 21:10 UTC
• Artiva Biotherapeutics, Inc. - 8-K Filing SEC EDGAR · November 9, 2026, 21:07 UTC
• Artiva Biotherapeutics, Inc. - 10-Q Filing SEC EDGAR · November 9, 2026, 21:04 UTC